|Bid||54.95 x 3100|
|Ask||55.72 x 100|
|Day's Range||54.40 - 55.23|
|52 Week Range||37.38 - 55.43|
|PE Ratio (TTM)||77.11|
|Dividend & Yield||1.06 (1.94%)|
|1y Target Est||N/A|
The Federal Reserve, American Express, and eBay will be the big stories on Wednesday as tax reform continues to dominate the Washington-related headlines.
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
On October 18, 2017, Abbott Laboratories will release its 3Q17 earnings results. Abbott stock was trading at its 52-week high of $55.4 on October 10.